EFFICACY OF LANSOPRAZOLE IN ERADICATION OF HELICOBACTER-PYLORI

Fifty-eight Helicobacter pylori-positive ulcer patients received omepr azole 20 mg (n = 15), or lansoprazole 30 mg (n = 23), lansoprazole 60 mg (n = 13), or E3810 20 mg (n = 7) q.d. Another 63 H. pylori-positive ulcer patients received lansoprazole and clarithromycin for 2 weeks. Patients received lansoprazole 30 mg and clarithromycin 400 mg (group 1, n = 22), lansoprazole 30 mg and clarithromycin 800 mg (group 2, n = 12), or lansoprazole 60 mg and clarithromycin 800 mg (group 3, n = 29 ). Neither proton pump inhibitor (PPI) was capable of eradication by m onotherapy, but the clearance rates in the lansoprazole group were 60. 9 and 69.2%, which were higher than those for omeprazole (p < 0.05). I n the dual therapy, eradication rates were 50, 50, and 72.4% in groups 1, 2, and 3, respectively, Minor side effects were observed in one ca se each in groups 1 and 3. Lansoprazole monotherapy proved more effica cious than omeprazole monotherapy, but it was unable to eradicate H. p ylori. Dual therapy with lansoprazole 60 mg and clarithromycin 800 mg was an efficacious and safe regimen for H. pylori eradication in this study.